The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Also known as: Apolipoprotein A-1, Apolipoprotein A1 Cardio IQ, Cardio IQ Apolipoprotein A-1
Also known as: Apolipoprotein B Cardio IQ, Cardio IQ Apolipoprotein B
Also known as: Cardio IQ hs-CRP , hsCRP Cardio IQ
Also known as: Cardio IQ Lipid Panel, Lipid Panel Cardio IQ, Lipids
Also known as: Cardio IQ Lipoprotein (a), Lipoprotein a Cardio IQ
Also known as: Ion Mobility, Cardio IQ Lipoprotein Fractionation, Ion Mobility , HDL Subfractions, IDL Subfractions, LDL Subfractions, Lipoprotein Fraction, Lipoprotein Fractionation, Lipoprotein Fractionation Ion Mobility Cardio IQ, Quest Diagnostics has replaced the VAP® Cholesterol Test with Lipoprotein Fractionation, Ion Mobility, Cardio IQ™ test
The Comprehensive Cardiovascular Risk Assessment Panel panel contains 12 tests with 32 biomarkers.
The Comprehensive Cardiovascular Risk Assessment Panel is a meticulously curated set of diagnostic tests designed to provide an in-depth analysis of an individual's risk for cardiovascular disease (CVD).
This panel goes beyond the traditional lipid profile to include advanced biomarkers for endothelial dysfunction, lipid particle size and concentration, inflammation, and genetic predisposition to atherosclerosis. With markers such as ADMA/SDMA, various apolipoproteins, hs-CRP, and more, this panel offers a multifaceted approach to understanding the complex interplay between different physiological factors that contribute to cardiovascular health.
By integrating these diverse measures, healthcare providers can develop more personalized and effective strategies for preventing and managing heart disease, offering patients a comprehensive overview of their cardiovascular risk profile.
Test Descriptions and Values:
ADMA/SDMA: These are markers of endothelial dysfunction, which is an early sign of cardiovascular disease (CVD). Elevated levels of ADMA (asymmetric dimethylarginine) and SDMA (symmetric dimethylarginine) can inhibit nitric oxide production, leading to impaired vasodilation and increased risk of atherosclerosis.
Apolipoprotein A-1, Cardio IQ™: This is the major protein component of high-density lipoprotein (HDL) in plasma. Higher levels are protective against CVD as Apo A-1 helps to clear cholesterol from cells and atheromas.
Apolipoprotein B, Cardio IQ™: This is the main component of low-density lipoprotein (LDL) and is a better indicator than LDL cholesterol alone in assessing cardiovascular risk as it reflects the number of atherogenic particles.
CARDIO IQ(R) Lp-PLA2 Activity: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme involved in the inflammation of blood vessels and is a risk factor for CVD, especially in predicting risk of stroke and coronary heart disease.
CARDIO IQ(R) Myeloperoxidase (MPO): MPO is an enzyme released by white blood cells during inflammation. Elevated levels can indicate vascular inflammation and increased risk of CVD.
hs-CRP, Cardio IQ™: High-sensitivity C-reactive protein is a marker of inflammation and is associated with higher risk of heart attacks and strokes. It can predict the occurrence of cardiovascular events in individuals with no apparent CVD.
Lipid Panel, Cardio IQ™: This includes measurement of total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides. These levels are directly implicated in cardiovascular health.
Lipoprotein (a), Cardio IQ™: Lp(a) is a particle that carries cholesterol and has pro-inflammatory and pro-thrombotic properties. Elevated Lp(a) levels are a genetic risk factor for atherosclerotic diseases.
Lipoprotein Fractionation, Ion Mobility, Cardio IQ™: This test provides detailed information about the size and density of lipoprotein particles. Small, dense LDL particles are more atherogenic than larger, buoyant ones.
Omega-3 and -6 Fatty Acids, Plasma: These fatty acid levels are indicative of dietary intake and can influence inflammatory processes and cell membrane function, which have roles in CVD risk.
OxLDL: Oxidized LDL is a form of LDL cholesterol that has been modified by oxidation. It is thought to be more atherogenic and is involved in the development of atherosclerosis.
TMAO (Trimethylamine N-Oxide): TMAO is a metabolite associated with gut microbiota that has been implicated in promoting atherosclerosis and is linked to increased risk for CVD events.
This panel gives a detailed picture of an individual's risk for cardiovascular disease, focusing on cholesterol particles, inflammation, and genetic predisposition, allowing for targeted risk management strategies.